![]() | |
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 5–8 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H27F5N6O3 |
Molar mass | 566.533 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Telcagepant ( INN) (code name MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co. [1]
In the acute treatment of migraine, it was found to have equal efficacy to rizatriptan [2] and zolmitriptan. [3]
A Phase IIa clinical trial studying telcagepant for the prophylaxis of episodic migraine was stopped on March 26, 2009, after the "identification of two patients with significant elevations in serum transaminases". [4] A memo to study locations stated that telcagepant had preliminarily been reported to increase the hepatic liver enzyme alanine transaminase (ALT) levels in "11 out of 660 randomized (double-blinded) study participants." All study participants were told to stop taking the medication. [5]
In July 2011, Merck announced that it had discontinued development of telcagepant. [6]
![]() | |
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 5–8 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H27F5N6O3 |
Molar mass | 566.533 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Telcagepant ( INN) (code name MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co. [1]
In the acute treatment of migraine, it was found to have equal efficacy to rizatriptan [2] and zolmitriptan. [3]
A Phase IIa clinical trial studying telcagepant for the prophylaxis of episodic migraine was stopped on March 26, 2009, after the "identification of two patients with significant elevations in serum transaminases". [4] A memo to study locations stated that telcagepant had preliminarily been reported to increase the hepatic liver enzyme alanine transaminase (ALT) levels in "11 out of 660 randomized (double-blinded) study participants." All study participants were told to stop taking the medication. [5]
In July 2011, Merck announced that it had discontinued development of telcagepant. [6]